secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-027947
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q2 2023 net sales $137.1M (-2.3% YoY); Adjusted EBITDA $28.2M (+26%); FY2023 guidance issued
--------------------------------------------------------------------------------

- Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.
- Adjusted EBITDA $28.2M, up 26.1% YoY; Non-GAAP EPS $0.14 vs $0.10.
- FY2023 guidance: net sales $490-505M, adjusted EBITDA $75-80M, Non-GAAP EPS ($0.24)-($0.20).
- Repaid $60.3M of term loan and revolver; net leverage ratio reduced to 4.33 from 5.50.
- Closed sale of Wound Business for $31M in net proceeds, used to repay debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/bvs-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer